EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial

Tenecteplase-Thrombolyse beim Schlaganfall bis 24 Stunden nach Symptombeginn mit Perfusionsbildgebung: die randomisierte klinische Studie CHABLIS-T II

Xin Cheng iD, Lan Hong iD, Longting Lin iD, Leonid Churilov iD, Yifeng Ling iD, Nan Yang, Jianliang Fu iD, Guozhi Lu, Yunhua Yue, Jin Zhang iD, Feng Wang iD, Ziran Wang und 24 weitere

Stroke · 2025-02 · 56 (2) · 344-354

DOI: 10.1161/strokeaha.124.048375 ↗

Auf einen Blick

Bei 224 Patient:innen mit ischämischem Schlaganfall im Zeitfenster von 4,5 bis 24 Stunden steigerte Tenecteplase die Reperfusion, änderte die klinischen Ergebnisse nach 90 Tagen aber nicht.

Fragestellung

Wirkt und ist Tenecteplase bei ischämischem Schlaganfall mit Gefäßverschluss im erweiterten Zeitfenster bis 24 Stunden sicher?

Methode

Randomisierte klinische Studie in China; 224 Patient:innen mit günstigem Penumbra-Profil und groß-/mittelkalibrigem Gefäßverschluss; 1:1 Tenecteplase 0,25 mg/kg i.v. vs. beste medizinische Behandlung.

Ergebnisse

Primärer Endpunkt: 33,3 % (37/111) vs. 10,8 % (12/113); adjustiertes RR 3,0 (95 %-KI 1,6–5,7; P=0,001). Rekanalisation: 35,8 % vs. 14,3 %; adjustiertes RR 2,5 (95 %-KI 1,4–4,4; P=0,002).

Schlussfolgerung der Autor:innen

Tenecteplase 0,25 mg/kg i.v. erhöhte die Reperfusion ohne symptomatische intrakranielle Blutung, veränderte die klinischen Ergebnisse nach 90 Tagen aber nicht.

Kernaussagen

  • 224 Patient:innen mit ischämischem Schlaganfall, 4,5 bis 24 Stunden nach last known well
  • Tenecteplase steigerte Reperfusion und Rekanalisation
  • Kein Unterschied in den klinischen Ergebnissen nach 90 Tagen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Stroke, 2025-02. Verfasst von Xin Cheng und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fuda…. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Ischemic Stroke, Perfusion Imaging, Stroke. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 30 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window. METHODS: Patients with ischemic stroke presenting 4.5 to 24 hours from the last known well, with a favorable penumbral profile and an associated large/medium vessel occlusion, were randomized 1:1 to either 0.25 mg/kg tenecteplase or the best medical treatment. A favorable penumbral profile was defined as a hypoperfusion lesion volume to infarct core volume ratio >1.2, with an absolute volume difference >10 mL, and an ischemic core volume 50% of the involved ischemic territory. Secondary outcomes included recanalization, infarct growth, major neurological improvements, change in the National Institutes of Health Stroke Scale score, hemorrhagic transformation within 24 to 48 hours, systemic bleeding at discharge, and modified Rankin Scale (score 0–1, score 0–2, score 5–6, and modified Rankin Scale distribution) at 90 days. The comparison of the primary outcome between groups was conducted using modified Poisson regression with a log-link function and robust error variance, adjusted for time from the last known well to randomization, the site of vessel occlusion, and planned endovascular treatment. RESULTS: Among 224 enrolled patients, 111 were assigned to receive tenecteplase and 113 to receive the best medical treatment (including 23% [n=26] of participants who received intravenous tissue-type plasminogen activator). The mean (SD) age of the tenecteplase group and the best medical treatment group was 64.2 (10.4) and 63.6 (11.0) years old, with 72.1% (n=80) and 70.8% (n=80) male enrolled, respectively. A proportion of 54.9% (n=123) of patients were transferred to the catheter room for preplanned endovascular treatment. The primary outcome occurred in 33.3% (n=37) of the tenecteplase group versus 10.8% (n=12) in the best medical treatment group (adjusted relative risk, 3.0 [95% CI, 1.6–5.7]; P =0.001). Tenecteplase significantly increased the recanalization rate compared with the best medical treatment (35.8% [n=39] versus 14.3% [n=16], adjusted relative risk, 2.5 [95% CI, 1.4–4.4]; P =0.002). There were no significant differences in clinical efficacy outcomes or rates of hemorrhagic transformation between the groups. CONCLUSIONS: Administered at a dose of 0.25 mg/kg intravenously, tenecteplase increased reperfusion without symptomatic intracranial hemorrhage in patients with ischemic stroke selected by imaging in late-time window treatment but did not change clinical outcomes at 90 days. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04516993.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsIschemic StrokePerfusion ImagingStrokeTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorAgedFemaleHumansMaleMiddle AgedTime FactorsTreatment Outcome

Stichwörter der Autor:innen

intracranial hemorrhagesischemic strokereperfusiontenecteplasethrombolytic therapy

Substanzen

Fibrinolytic AgentsTenecteplaseTissue Plasminogen Activator

Autor:innen und Institutionen

  • Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China (X.C., L.H., Y.L., Yiran Zhang, X.L., S.…
  • Department of Neurology, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia (L.L., M.P.).
  • Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (L.C.).
  • Department of Neurology, Puer People's Hospital, China (N.Y.).
  • Department of Neurology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, China (J.F.).
  • Department of Neurology, Hexigten Traditional Chinese and Mongolian Medicine Hospital, Chifeng, China (G.L.).

ORCID-Profile: Xin Cheng, Lan Hong, Longting Lin, Leonid Churilov, Yifeng Ling, Jianliang Fu, Jin Zhang, Feng Wang, Xiaoyu Zhou, Danhong Wu, Liandong Zhao, Qijin Zhai, Xiaofei Yu, Qi Fang, Diwen Zhang, Yu Geng, Yangmei Chen, Yiran Zhang, Siyuan Li, Mark Parsons, Qiang Dong

Zitieren

APA

Cheng, X., Hong, L., Lin, L., Churilov, L., Ling, Y., Yang, N., Fu, J., Lu, G., Yue, Y., Zhang, J., Wang, F., Wang, Z., Zhao, Y., Zhou, X., Peng, Z., Wu, D., Zhao, L., Zhai, Q., Yu, X., …, & CHABLIS-T II Collaborators (2025). Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial. Stroke, 56(2), 344-354. https://doi.org/10.1161/strokeaha.124.048375

Vancouver

Cheng X, Hong L, Lin L, Churilov L, Ling Y, Yang N, et al. Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial. Stroke. 2025;56(2):344-354. doi:10.1161/strokeaha.124.048375

BibTeX
@article{Cheng2025,
  author = {Cheng, Xin and Hong, Lan and Lin, Longting and Churilov, Leonid and Ling, Yifeng and Yang, Nan and Fu, Jianliang and Lu, Guozhi and Yue, Yunhua and Zhang, Jin and Wang, Feng and Wang, Ziran and Zhao, Yanxin and Zhou, Xiaoyu and Peng, Zhaolong and Wu, Danhong and Zhao, Liandong and Zhai, Qijin and Yu, Xiaofei and Fang, Qi and Shao, Xiangzhong and Tang, Ying and Zhang, Diwen and Geng, Yu and Zhang, Yue and Fan, Bosheng and Zhang, Bing and Yin, Congguo and Chen, Yangmei and Zhang, Yiran and Liu, Xinyu and Li, Siyuan and Yang, Lumeng and Parsons, Mark and Dong, Qiang and CHABLIS-T II Collaborators, CHABLIS-T II Collaborators},
  title = {Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {2},
  pages = {344--354},
  doi = {10.1161/strokeaha.124.048375}
}
Kostenlos starten →